Hurtsellers Christine
Transaction: 05/06/2026
BUY
Change
+17
Price
$14.83
Filing
05/07/2026
Type
BUY
John Hancock Preferred Income Fund III
HPS • Asset Management - Income
$13.61
▼ -0.07 (-0.51%)
Current price
EarningsLatest report: Jan 31, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$437.82M
Growth
-1.9%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 84.1%Positive free cash flow · 1.08Consistent free cash flow · 5/5Reasonable earnings multiple · 11.86Manageable debt level · 0.6
Financial data as of: Jan 31, 2026, 12:00 AM UTCLast earnings update: Apr 1, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$13.61
Change-0.51%
Shares Out32.17M
Market Cap$437.82M
Enterprise Value$706.79M
52W Range13.80 - 15.68
Beta0.68
P/E4.76
P/S4.31
P/B0.95
P/FCF6.10
EV/Sales6.96
Price$13.61
Change-0.51%
Shares Out32.17M
Market Cap$437.82M
Enterprise Value$706.79M
52W Range13.80 - 15.68
Beta0.68
P/E4.76
P/S4.31
P/B0.95
P/FCF6.10
EV/Sales6.96
EV/EBITDA8.41
EV/FCF9.85
Earnings Yield20.99%
FCF Yield16.39%
Dividend Yield18.60%
Gross Margin87.72%
Oper. Margin115.96%
Profit Margin84.07%
Debt/Eq0.60
Current Ratio9.41
Quick Ratio9.41
Revenue 5Y-1.90%
FCF 5Y0.94%
Volume40.09K
Avg Volume55.25K
Investment DNA
How strong this company looks for long-term investors
72
out of 100
Business Quality
Margins, moat, returns
77/100
Financial Strength
Debt, cash, stability
73/100
Growth Potential
Revenue and expansion
46/100
Price Attractiveness
Cheap or expensive today
71/100
Why this score▼
Stable or improving margins · 84.1%Positive free cash flow · 1.08Consistent free cash flow · 5/5Reasonable earnings multiple · 11.86Manageable debt level · 0.6Healthy liquidity · 9.41
Analyst view
No analyst data available now.
Insider Transactions
Recent executive and insider activity
Phelan Kenneth J
Transaction: 01/26/2026
BUY
Change
—
Price
$14.65
Filing
01/27/2026
Type
BUY
Phelan Kenneth J
Transaction: 11/12/2025
OTHER
Change
0
Price
Not reported
Filing
11/17/2025
Type
OTHER
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Hurtsellers Christine | BUY | +17 | $14.83 | 05/06/2026 | 05/07/2026 |
| Phelan Kenneth J | BUY | — | $14.65 | 01/26/2026 | 01/27/2026 |
| Phelan Kenneth J | OTHER | 0 | Not reported | 11/12/2025 | 11/17/2025 |
| Hurtsellers Christine | OTHER | 0 | Not reported | 11/12/2025 | 11/17/2025 |
| Georgountzos Effie | OTHER | 0 | Not reported | 06/16/2025 | 07/31/2025 |
| Wright Thomas Rowe | BUY | +794 | $13.79 | 04/08/2025 | 04/09/2025 |
| Bacic William K | BUY | +706 | $14.25 | 01/14/2025 | 01/15/2025 |
| Ellison Noni L | BUY | +740 | $15.26 | 12/23/2024 | 12/26/2024 |
| Nataupsky Jeff | OTHER | 0 | Not reported | 10/31/2024 | 11/06/2024 |
| Carrington Patricia | OTHER | 0 | Not reported | 09/26/2024 | 10/02/2024 |
| Bacic William K | OTHER | 0 | Not reported | 08/01/2024 | 08/08/2024 |
| Wright Thomas Rowe | OTHER | 0 | Not reported | 08/01/2024 | 08/08/2024 |
| Silva Fernando A | OTHER | 0 | Not reported | 07/01/2024 | 07/02/2024 |
| McCubbin Terence A | OTHER | 0 | Not reported | 05/13/2024 | 05/15/2024 |
| Garfield Dean | BUY | — | $13.88 | 01/02/2024 | 01/04/2024 |
| Ellison Noni L | BUY | +879 | $12.60 | 10/12/2023 | 10/16/2023 |
| McFetridge Andy | OTHER | 0 | Not reported | 10/06/2023 | 10/10/2023 |
| Feinberg Kristie | OTHER | 0 | Not reported | 05/16/2023 | 05/23/2023 |
| Lo York | OTHER | — | Not reported | 12/15/2022 | 12/23/2022 |
| PRUCHANSKY STEVEN R | SELL | — | $17.07 | 08/05/2022 | 08/09/2022 |